Ana María Gómez1,2, Angélica Imitola Madero1,2, Diana Cristina Henao Carrillo1,2, Martín Rondón3, Oscar Mauricio Muñoz4, Maria Alejandra Robledo1, Martín Rebolledo1, Maira García Jaramillo5, Fabian León Vargas6, Guillermo Umpierrez7,8. 1. Pontificia Universidad Javeriana, Bogotá, Colombia. 2. Hospital Universitario San Ignacio, Endocrinology Unit, Bogotá, Colombia. 3. Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Bogotá, Colombia. 4. Hospital Universitario San Ignacio, Department of Internal Medicine, Bogotá, Colombia. 5. Universidad EAN, Bogotá, Colombia. 6. Universidad Antonio Nariño, Bogotá, Colombia. 7. Department of Medicine, Emory University, Atlanta, GA, USA. 8. Division of Endocrinology, Metabolism and Lipids, Emory University, Atlanta, GA, USA.
Abstract
INTRODUCTION: Continuous glucose monitoring (CGM) is a better tool to detect hyper and hypoglycemia than capillary point of care in insulin-treated patients during hospitalization. We evaluated the incidence of hypoglycemia in patients with type 2 diabetes (T2D) treated with basal bolus insulin regimen using CGM and factors associated with hypoglycemia. METHODS: Post hoc analysis of a prospective cohort study. Hypoglycemia was documented in terms of incidence rate and percentage of time <54 mg/dL (3.0 mmol/L) and <70 mg/dL (3.9 mmol/L). Factors evaluated included glycemic variability analyzed during the first 6 days of basal bolus therapy. RESULTS: A total of 34 hospitalized patients with T2D in general ward were included, with admission A1c of 9.26 ± 2.62% (76.8 ± 13 mmol/mol) and mean blood glucose of 254 ± 153 mg/dL. There were two events of hypoglycemia below 54 mg/dL (3.0 mmol/L) and 11 events below 70 mg/dL (3.9 mmol/L) with an incidence of hypoglycemic events of 0.059 and 0.323 per patient, respectively. From second to fifth day of treatment the percentage of time in range (140-180 mg/dL, 7.8-10.0 mmol/L) increased from 72.1% to 89.4%. Factors related to hypoglycemic events <70 mg/dL (3.9 mmol/L) were admission mean glucose (IRR 0.86, 95% CI 0.79, 0.95, P < .01), glycemic variability measured as CV (IRR 3.12, 95% CI 1.33, 7.61, P < .01) and SD, and duration of stay. CONCLUSIONS: Basal bolus insulin regimen is effective and the overall incidence of hypoglycemia detected by CGM is low in hospitalized patients with T2D. Increased glycemic variability as well as the decrease in mean glucose were associated with events <70 mg/dL (3.9 mmol/L).
INTRODUCTION: Continuous glucose monitoring (CGM) is a better tool to detect hyper and hypoglycemia than capillary point of care in insulin-treated patients during hospitalization. We evaluated the incidence of hypoglycemia in patients with type 2 diabetes (T2D) treated with basal bolus insulin regimen using CGM and factors associated with hypoglycemia. METHODS: Post hoc analysis of a prospective cohort study. Hypoglycemia was documented in terms of incidence rate and percentage of time <54 mg/dL (3.0 mmol/L) and <70 mg/dL (3.9 mmol/L). Factors evaluated included glycemic variability analyzed during the first 6 days of basal bolus therapy. RESULTS: A total of 34 hospitalized patients with T2D in general ward were included, with admission A1c of 9.26 ± 2.62% (76.8 ± 13 mmol/mol) and mean blood glucose of 254 ± 153 mg/dL. There were two events of hypoglycemia below 54 mg/dL (3.0 mmol/L) and 11 events below 70 mg/dL (3.9 mmol/L) with an incidence of hypoglycemic events of 0.059 and 0.323 per patient, respectively. From second to fifth day of treatment the percentage of time in range (140-180 mg/dL, 7.8-10.0 mmol/L) increased from 72.1% to 89.4%. Factors related to hypoglycemic events <70 mg/dL (3.9 mmol/L) were admission mean glucose (IRR 0.86, 95% CI 0.79, 0.95, P < .01), glycemic variability measured as CV (IRR 3.12, 95% CI 1.33, 7.61, P < .01) and SD, and duration of stay. CONCLUSIONS:Basal bolus insulin regimen is effective and the overall incidence of hypoglycemia detected by CGM is low in hospitalized patients with T2D. Increased glycemic variability as well as the decrease in mean glucose were associated with events <70 mg/dL (3.9 mmol/L).
Authors: Lukas Schaupp; Klaus Donsa; Katharina M Neubauer; Julia K Mader; Felix Aberer; Bernhard Höll; Stephan Spat; Thomas Augustin; Peter Beck; Thomas R Pieber; Johannes Plank Journal: Diabetes Technol Ther Date: 2015-04-30 Impact factor: 6.118
Authors: Louis Monnier; Claude Colette; Anne Wojtusciszyn; Sylvie Dejager; Eric Renard; Nicolas Molinari; David R Owens Journal: Diabetes Care Date: 2016-12-30 Impact factor: 19.112
Authors: Ana M Gómez; Guillermo E Umpierrez; Oscar M Muñoz; Felipe Herrera; Claudia Rubio; Pablo Aschner; Richard Buendia Journal: J Diabetes Sci Technol Date: 2015-08-31
Authors: Rodolfo J Galindo; Grazia Aleppo; David C Klonoff; Elias K Spanakis; Shivani Agarwal; Priya Vellanki; Darin E Olson; Guillermo E Umpierrez; Georgia M Davis; Francisco J Pasquel Journal: J Diabetes Sci Technol Date: 2020-06-14